Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the second quarter ended June 30, 2013.
Orexigen also announced its plan to submit a Marketing Authorization Application (MAA) for Contrave(R) to the European Medicines Agency (EMA) utilizing the centralized procedure. Orexigen has met with the European rapporteurs to discuss the filing strategy of the MAA.
Hey, check out all the research scientist jobs. Post your resume today!
